Gainers

  • Agilon Health (NYSE:AGL) shares moved upwards by 115.7% to $60.08 during Thursday's regular session. The market value of their outstanding shares is at $463.9 million. As per the news, the Q1 earnings report came out yesterday.
  • Atara Biotherapeutics (NASDAQ:ATRA) stock moved upwards by 92.23% to $9.9. The market value of their outstanding shares is at $43.8 million.
  • Cross Country Healthcare (NASDAQ:CCRN) stock rose 29.52% to $13.1. The market value of their outstanding shares is at $325.5 million. As per the news, the Q1 earnings report came out today.
  • SenesTech (NASDAQ:SNES) stock rose 25.85% to $1.85. The company's market cap stands at $7.7 million.
  • OSR Holdings (NASDAQ:OSRH) shares moved upwards by 20.66% to $0.7. The market value of their outstanding shares is at $14.9 million.
  • Ernexa Therapeutics (NASDAQ:ERNA) stock moved upwards by 19.2% to $7.2. The market value of their outstanding shares is at $7.0 million.

Losers

  • enGene Therapeutics (NASDAQ:ENGN) shares decreased by 79.7% to $1.79 during Thursday's regular session. The company's market cap stands at $592.8 million.
  • Entrada Therapeutics (NASDAQ:TRDA) stock decreased by 58.86% to $6.59. The market value of their outstanding shares is at $622.2 million. The company's, Q1 earnings came out today.
  • Accuray (NASDAQ:ARAY) stock declined by 28.73% to $0.34. The market value of their outstanding shares is at $54.0 million. The company's, Q3 earnings came out yesterday.
  • Pharming (NASDAQ:PHAR) stock decreased by 27.6% to $11.88. The company's market cap stands at $1.1 billion. As per the press release, Q1 earnings came out today.
  • Apimeds Pharmaceuticals (AMEX:APUS) shares fell 26.42% to $1.44. The market value of their outstanding shares is at $24.5 million. As per the news, the Q4 earnings report came out 3 days ago.
  • Aspire Biopharma Holdings (NASDAQ:ASBP) stock fell 25.81% to $0.14. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.